American Association of Individual Investors5 lá
Why OS Therapies Incorporated’s (OSTX) Stock Is Down 25.00%
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate OS Therapies Incorporated before investing. In this article, we go over a few key ...
Business Wire19 lá
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung ...
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...
Yahoo Finance4 lá
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies previously disclosed that it completed a $7.1M financing, priced at $4.00 per share primarily with existing shareholders, that provides the company with sufficient cash runway into ...
ETF Daily News18 lá
OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital
OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports.
ETF Daily News4 lá
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals: MarketBeat News
As per the terms of the agreement, OS Therapies will pay an aggregate purchase price of $8 million. This will include $0.5 million in cash and $7.5 million worth of OS Therapies’ common shares.
Business Wire5 lá
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate ...
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it ...